Gartner IT

At a glance

One-line thesis. Gartner is a genuinely elite subscription-research franchise — 68% gross margin, ~21% ROIC, ~14% FCF yield — that the market has cut by two-thirds because growth stalled and AI threatens the core product; at ~10× forward earnings the price already reflects a lot of pain, so this is a cheap-quality mean-reversion trade for a tactical sleeve, not a buy-and-forget compounder.

1. What it is

Gartner, Inc. (NYSE: IT) is a Stamford, Connecticut research-and-advisory company founded in 1979. Its core product is a subscription to syndicated research — on-demand access to analyst reports, data, benchmarks, and one-on-one analyst inquiry — sold mainly to IT and business leaders. Around that it runs a Conferences business (the Gartner Symposium/Xpo series) and a Consulting arm (bespoke advisory and IT-cost/sourcing work). Fiscal year ends December 31. CEO Eugene (Gene) Hall has run the company for two decades.

The economic engine is Contract Value (CV) — the annualized value of all subscription research contracts. Because research is recurring and renews at high rates, CV growth is the number that drives the stock. In Q1'26 total CV was $5.3B, +1.0% YoY FX-neutral — a sharp deceleration from the double-digit CV growth of the 2021–2023 era, and the proximate cause of the stock's collapse.

Revenue mix (FY2025, from filings):

• By segment (FMP classification): the vast majority is the Research/Insights segment (~$5.3B, ~82% of revenue and essentially all of the profit), with Conferences/Events ~$0.64B and Consulting ~$0.55B. In Q1'26 the segments grew: Insights +3.1% reported (−0.1% FX-neutral), Conferences +7.9%, Consulting −14.7% — i.e. the crown-jewel research segment is flat FX-neutral and consulting is actively shrinking.
• By geography (FY2025): United States & Canada $4.03B (~62%) · Europe/Middle East/Africa $1.69B (~26%) · Other International $0.77B (~12%). The base is North-America-heavy but meaningfully global.

The company generated $6.50B revenue in FY2025 (+3.7% YoY) and ~$1.18B free cash flow — a cash machine whose growth rate, not its profitability, is in question.

2. The expert thesis (no coverage — stated plainly)

There is no expert coverage of Gartner in the Synthos knowledge base. total_claims = 0; there are zero net-bullish voices and zero traceable claim_ids. Nothing in this note is attributed to an outside expert panel, because none exists in our KB for this ticker.

That is an honest and material fact: unlike our conviction-track names (e.g. Eli Lilly, 13 net-bullish voices and 251 reconciled claims), this verdict is entirely fundamentals- and quant-driven. It rests on the reported financials (FMP), analyst consensus estimates (labeled as estimates), management's own SEC-filed guidance (half-weighted, §9), and the technical/valuation picture — not on distilled expert conviction. Weight it accordingly: there is no independent-voice breadth here to corroborate or challenge the numbers.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.

Synthos fair value = the base case, ~$175 (+28%), with the full $95–$250 span as the honest range. This anchor sits essentially on top of the Street's $174 consensus — not because we're anchoring to it, but because the independent math (a stalled-but-cash-rich franchise deserves a low-teens multiple on ~$15 of forward EPS) lands in the same place. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). Gartner is neither right now — it is a high-return franchise whose growth has stalled, which is the opposite of exponential:

• Forward growth: consensus revenue rises from $6.50B (FY25) → ~$6.43B (FY26E) → ~$6.72B (FY27E) — i.e. flat-to-low-single-digit. Consensus EPS ~$13.71 (FY26E) → ~$15.38 (FY27E) → ~$29.69 (FY30E), but the FY29–30 EPS figures rest on just one analyst and lean heavily on relentless buybacks, not organic growth. Treat the out-years as thinly-covered estimates.
• Acceleration (the 2nd derivative) is negative: revenue growth ran +15.7% (FY22) → +7.9% (FY23) → +6.1% (FY24) → +3.7% (FY25) → −1.5% (Q1'26). CV growth has decelerated to ~1% FX-neutral. This is a franchise braking, not accelerating — precisely why the market re-rated it. Per our flagship philosophy we hunt forward next-exponentials; IT is a trailing compounder that has lost its growth.
• Room to run: the addressable market (enterprise research/advisory) is large but Gartner already leads it; there is no untapped 10× TAM wedge here. AI is the swing factor and it cuts both ways — it could make analysts more productive (margin tailwind) or let customers self-serve insight they used to buy (revenue threat).
• Reinvestment runway: capital returns, not reinvestment, are the story — capex is tiny (~1.7% of revenue) and the company funnels essentially all FCF into buybacks (§9). That supports EPS but is not an exponential-growth flywheel.

Exponential Potential: Low (3/10). Own IT — if at all — for a valuation rebound and buyback-driven EPS, not for exponential expansion. The realistic upside is mean reversion, not compounding into a multibagger.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $6.50B, +3.7% (FY24 $6.27B, +6.1%; FY23 $5.91B). The multi-year deceleration is the whole story. Q1'26 revenue $1.51B, −1.5% reported (−4.3% FX-neutral) — a genuinely negative print.
• Margins: gross 68.2% TTM, EBITDA ~19.5% TTM, net 11.4% TTM. Adjusted EBITDA (ex-divested Digital Markets) ran $395M in Q1'26, +5.7% — margins are holding even as revenue softens, which is the bull's comfort.
• Earnings: GAAP net income $729M FY25 (EPS $9.68) — down from $1.25B/$16.12 in FY24, but FY24 was flattered by large one-off items (a ~$231M positive "other income" line and a negative tax). On an adjusted basis EPS is running ~$13/yr (Q1'26 adjusted EPS $3.32, +11.4%). Use the adjusted/forward figures, not the noisy GAAP swing, for valuation.
• Cash flow (the real quality tell): FY25 operating CF $1.29B, capex just −$115M, FCF ~$1.18B — a ~13.8% FCF yield on today's market cap. Q1'26 FCF $371M, +28.7% YoY. Cash generation is excellent and improving even as reported revenue dips.
• Balance sheet: cash $1.72B, total debt $3.62B, net debt ~$1.90B, net-debt/EBITDA 1.26× — investment-grade (S&P-style FMP rating A−) and easily serviceable (interest coverage ~15×). Caveat: total stockholders' equity is only $320M and tangible book is negative — a direct consequence of ~$9.0B of cumulative treasury stock from years of buybacks. The thin equity is an accounting artifact of capital return, not distress, but it means there is little balance-sheet "floor" under the stock.

6. Valuation — priced in or room?

For once the interesting question is whether a stock is too cheap. On trailing numbers IT trades at 13.4× GAAP EPS, 1.7× EV/sales, 8.5× EV/EBITDA, with a ~13.8% free-cash-flow yield. On forward consensus it's ~9.9× FY26E EPS ($13.71) and ~8.9× FY27E ($15.38) — a mid-single-digit-grower multiple for a business with 68% gross margins and ~21% ROIC. That is objectively inexpensive versus its own history (the stock changed hands above 30× at the 2024 peak) and versus quality-compounder norms.

The bear's rebuttal is that the multiple is low for a reason: if Contract Value growth is structurally impaired by AI substitution, then "cheap" is a value trap and the correct multiple is 8–10×. The reverse-DCF read: at ~$136 the market is pricing roughly flat-to-low-single-digit perpetual growth — a genuinely pessimistic assumption for a franchise that grew CV double-digits as recently as 2023. If growth merely stabilizes at low-single-digits (our base), a re-rate to ~11–12× on ~$15 forward EPS gets you to ~$175.

Street targets (context): consensus $174, high $240, low $120; the grade split is 5 Buy · 10 Hold · 3 Sell → Hold. Our ~$175 base fair value lands right at consensus — the Street and the independent math agree this is fairly-to-modestly-cheap, with the whole debate being about whether growth returns. Not a clean value buy; a cheap-franchise-in-a-fundamental-de-rating buy.

7. Technicals (from the tech block)

• Trend: down, decisively. $136 sits below the 50-DMA ($149) and far below the 200-DMA ($195), with the 50 below the 200 (death-cross posture). MACD −6.3 (negative).
• Location: −66% off the 52-week high (~$400), only +8% off the 52-week low (~$126) — this is a stock sitting near the bottom of a brutal decline, with a max drawdown of −75% from peak. There is no technical evidence of a bottom yet.
• Momentum: RSI(14) 38 — weak, approaching but not yet at classic oversold (<30); no reversal signal.
• Relative strength (the tell): IT −66% 12-mo vs SPY +21% and QQQ +30%; −11.9% 3-mo while SPY was +13.7% and QQQ +22%. Persistent, severe underperformance of both the market and tech.
• Read: technicals contradict any rush to buy — this is a falling knife with no confirmed base. The value case is real, but the tape says scale in slowly / wait for stabilization rather than back up the truck. A move back above the 50-DMA (~$149), or a post-earnings CV re-acceleration, would be the first technical "all-clear."

8. Moat & competitive position

Gartner's moat is genuine and durable: (1) brand and data flywheel — decades of proprietary research, benchmarks, and the "Magic Quadrant" franchise that both buyers and vendors treat as an industry standard; (2) recurring, high-renewal subscription revenue with ~68% gross margins; (3) scale — the largest analyst bench and event footprint in the category, hard to replicate. High client retention and wallet-share expansion have historically driven double-digit CV growth. The open question the whole thesis turns on is whether generative AI erodes the willingness to pay for syndicated research — management itself flags "keeping pace with technological developments in AI" as a top risk factor (§9).

Peer set (market cap, from FMP — note these are loose "consulting/IT-services" comps, not pure research peers): CDW $17.0B, Corpay (CPAY) $23.0B, Fortive $19.1B, GoDaddy $11.7B, CGI (GIB) $14.4B, Jacobs Solutions (J) $15.1B, Leidos $13.7B, Logitech $13.5B, Trimble $12.4B, United Microelectronics (UMC) $61.2B. Gartner has no clean public pure-play comparator; it is best understood as a subscription-research franchise whose economics (margin, FCF, ROIC) sit at the high end of this group, which is part of why the de-rating looks overdone if growth stabilizes.

9. Management, capital allocation & guidance

• Capital allocation: aggressively shareholder-return-focused. FY25 saw ~$1.99B of buybacks and the Board added $600M to the repurchase authorization in April 2026; Q1'26 alone repurchased 3.3M shares for $535M. There is no dividend. Capex is minimal (~1.7% of revenue). This is a deliberate "compound EPS via share-count reduction" model — powerful when the stock is cheap (as now), but it has left the balance sheet with thin/negative tangible equity (§5). CEO Gene Hall has a long, credited tenure.
• Insider activity: the sampled Form 4s (through 2026-07-01) are routine — RSU vesting, tax-withholding in-kind dispositions, and small equity-award-related acquisitions by officers/directors. No cluster of large discretionary open-market selling in the window; nothing alarming, but nothing that reads as a conviction insider "buy the dip" signal either.
• Management's own guidance — half-weighted (self-interested): Guidance was available and reads as a genuine earnings release (SEC 8-K Item 2.02, filed 2026-05-05 with the Q1'26 results). In their own words, management raised full-year 2026 guidance for Adjusted EBITDA (ex-divested operation), Adjusted EPS, and free cash flow, and CEO Gene Hall stated that "Contract Value accelerated in the quarter" with Insights revenue, Adjusted EBITDA, Adjusted EPS, and FCF "ahead of expectations." Treat this as management's self-interested framing (half-weight): the raised guidance and claimed CV acceleration are the bull's strongest near-term evidence, but note the same quarter still printed −1.5% reported revenue and only +1.0% FX-neutral CV — so "accelerated" is off a very low base. The full-year dollar guidance figures are in the earnings supplement, which is beyond the SEC 8-K text captured here.

10. Catalysts & what to watch

• Next earnings: 2026-08-04 (Q2'26; Street EPS $3.78, revenue ~$1.65B). The single most important line is Contract Value growth (FX-neutral) — is the Q1 "acceleration" real and building, or noise?
• CV / renewal trajectory: two or more quarters of accelerating CV would validate the bull case and likely re-rate the multiple; further deceleration validates the bear.
• AI disclosure: any concrete evidence — positive (AI-driven new products, pricing power on AI-strategy advice) or negative (renewal/churn pressure) — reframes the entire thesis.
• Consulting stabilization: Consulting −14.7% in Q1'26; a return toward flat would remove a visible drag.
• Buyback pace: continued heavy repurchases at ~10× earnings mechanically lift EPS and signal management conviction.

Thesis tripwires (what would change the call): FX-neutral CV growth turning negative; adjusted-EPS or FCF guidance cut on a subsequent print; evidence of AI-driven subscription churn; or a break below the ~$126 52-week low on heavy volume.

11. Key risks

• The de-rating may be fundamental, not sentiment (structural): CV growth has fallen to ~1% and Q1'26 revenue was negative. If this is the new normal, the low multiple is correct and there is no rebound. This is the core risk.
• AI substitution: generative AI could erode willingness to pay for syndicated research — management's own top-listed risk factor. Unproven either way, but existential to the moat if it breaks the wrong way.
• No margin of safety in book value: ~$320M equity and negative tangible book (buyback artifact) mean little balance-sheet floor; the case rests on cash flows continuing.
• No expert corroboration: zero Synthos KB coverage — no independent-voice breadth to confirm the quant/fundamental read. Lower conviction by construction.
• Falling-knife technicals: −66% 12-mo, below both moving averages, no confirmed base — buying here risks further downside before any reversion.
• Concentration: the Research/Insights segment is ~82% of revenue and essentially all the profit; a problem there is a problem everywhere.

12. Verdict, position sizing & monitoring

Buy — Tactical. Gartner is a demonstrably elite franchise — 68% gross margin, ~21% ROIC, ~14% FCF yield, an entrenched brand moat — that the market has cut by two-thirds because its growth engine stalled and AI cast a shadow over the product. At ~10× forward earnings with management raising adjusted-EPS/FCF guidance and buying back ~$0.5B of stock a quarter, a lot of pessimism is already priced in, and the risk/reward skews to a mean-reversion trade toward ~$175 (+28%). But this is explicitly not a core compounder today: growth is negative on the latest print, the AI threat is unresolved, there is zero expert-KB corroboration, and the chart is a falling knife.

• Sizing: tactical/satellite, ~1–3%, scaled in rather than lump-summed, with a hard mental stop below the ~$126 52-week low. This is a value/mean-reversion position with a defined thesis (CV re-acceleration), not a flagship core holding.
• Monitoring: re-underwrite on the §10 tripwires; the 2026-08-04 CV print is the pivotal data point. Formal re-score each earnings release.
• Single biggest risk: that the collapse is telling the truth — that AI and a maturing market have structurally broken Gartner's growth, in which case "cheap" gets cheaper.

This verdict is logged as a tracked Synthos call as of 2026-07-03 at $136.32.

Provenance & disclosures

• Traceability: 0 KB claims, breadth 0 — there is no expert coverage of IT in the Synthos knowledge base. This note is fundamentals- and quant-driven; no conviction is attributed to experts. Fabricated conviction is structurally impossible (claim-ID reconciliation) — and here there are simply none to cite.
• Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K filed 2026-05-05. Forward figures are analyst consensus (FMP), labeled as estimates; note FY29–30 EPS rests on a single analyst.
• Management caveat: the raised FY26 guidance and "CV accelerated" commentary are management's own, self-interested framing — half-weighted by design.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").